Literature DB >> 24366425

Urinary excretion of high molecular weight adiponectin is an independent predictor of decline of renal function in type 2 diabetes.

Stefan Kopf1, Dimitrios Oikonomou, Maximilian von Eynatten, Meinhard Kieser, Dietmar Zdunek, Gregor Hess, Michael Morcos, Carol Forsblom, Angelika Bierhaus, Per-Henrik Groop, Peter P Nawroth, Per M Humpert.   

Abstract

Adiponectin and urinary adiponectin excretions have been ascribed a function in glomerular physiology and seem to indicate vascular disease in diabetes. The aim of this study was to compare the urinary excretion of albumin and adiponectin as predictors for decline of renal function in patients with type 2 diabetes and early kidney disease. Over 141 patients were screened for renal function (estimated GFR, ml/min*1.73 m(2)), albumin excretion rate (AER, mg/24 h), total as well as high molecular weight (HMW) urinary adiponectin excretion (ng/mol u-creatinine). AER and adiponectin excretion were studied as predictors of renal function after 1 year. After 1 year, 36 patients were in the upper quartile of eGFR decline and defined as progressors (delta eGFR = - 12.3 ± 6.3) while the remaining 105 patients were defined as non-progressors (delta eGFR = 1.4 ± 6.0). At baseline, HMW-adiponectin excretion was positively correlated with HbA1c (p < 0.001) and negatively with eGFR (p < 0.001), but not with AER (p = 0.14). Progressors showed increased urinary HMW-adiponectin at baseline (158[IQR41/479] vs. 65[24/168] ng/mol; p < 0.01), while total adiponectin (182[101/1534] vs. 345[118/1361] ng/mol) and AER (48[23/109] vs. 46[25/108] mg/24 h) excretion showed no differences between the groups. Multivariate logistic regression showed that HMW-adiponectin excretion was an independent predictor of renal progression in all patients (OR 1.86 [95 % CI 1.34-2.59]; p < 0.01), especially in those (n = 45) with normal AER at baseline (OR 2.16 [95 % CI 1.1-4.56]; p < 0.05). Urinary HMW-adiponectin but not AER improved the prediction of progressors in ROC analysis (AUC 0.72 [95 % CI 0.63-0.81] vs. 0.80 [95 % CI 0.71-0.90], p < 0.05). In conclusion, urinary HMW-adiponectin excretion may identify diabetes patients at increased risk for progression of kidney disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24366425     DOI: 10.1007/s00592-013-0542-2

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  8 in total

1.  Renoprotective effects of berberine as adjuvant therapy for hypertensive patients with type 2 diabetes mellitus: Evaluation via biochemical markers and color Doppler ultrasonography.

Authors:  Peifeng Dai; Junhua Wang; Lin Lin; Yanyan Zhang; Zhengping Wang
Journal:  Exp Ther Med       Date:  2015-06-22       Impact factor: 2.447

2.  Renal Function in Type 2 Diabetes Following Gastric Bypass.

Authors:  Adrian T Billeter; Stefan Kopf; Martin Zeier; Katharina Scheurlen; Lars Fischer; Thilo M Schulte; Hannes G Kenngott; Barbara Israel; Philipp Knefeli; Markus W Büchler; Peter P Nawroth; Beat P Müller-Stich
Journal:  Dtsch Arztebl Int       Date:  2016-12-09       Impact factor: 5.594

3.  Adiponectin is associated with early diabetic kidney disease in adults with type 1 diabetes: A Coronary Artery Calcification in Type 1 Diabetes (CACTI) Study.

Authors:  Petter Bjornstad; Laura Pyle; Gregory L Kinney; Marian Rewers; Richard J Johnson; David M Maahs; Janet K Snell-Bergeon
Journal:  J Diabetes Complications       Date:  2016-06-14       Impact factor: 2.852

4.  Urinary adiponectin as a new diagnostic index for chronic kidney disease due to diabetic nephropathy.

Authors:  Shinnosuke Yamakado; Hiroki Cho; Mikio Inada; Mika Morikawa; Yong-Huang Jiang; Kenji Saito; Kazunari Nakaishi; Satoshi Watabe; Hitomi Takagi; Mugiho Kaneda; Akira Nakatsuma; Masaki Ninomiya; Hitomi Imachi; Takeshi Arai; Takuo Yoshimoto; Koji Murao; Jyun-Hao Chang; Shih-Min Chen; Yi-Chen Shih; Min-Jing Zeng; Liang-Yin Ke; Chu-Huang Chen; Teruki Yoshimura; Toshiaki Miura; Etsuro Ito
Journal:  BMJ Open Diabetes Res Care       Date:  2019-05-30

Review 5.  Diabetic kidney disease: new clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on "The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function".

Authors:  Giuseppe Pugliese; Giuseppe Penno; Andrea Natali; Federica Barutta; Salvatore Di Paolo; Gianpaolo Reboldi; Loreto Gesualdo; Luca De Nicola
Journal:  J Nephrol       Date:  2020-02       Impact factor: 3.902

6.  Urinary adiponectin and albuminuria in non-diabetic hypertensive patients: an analysis of the ESPECIAL trial.

Authors:  Seung Seok Han; Eunjin Bae; Shin Young Ahn; Sejoong Kim; Jung Hwan Park; Sung Joon Shin; Sang Ho Lee; Bum Soon Choi; Ho Jun Chin; Chun Soo Lim; Suhnggwon Kim; Dong Ki Kim
Journal:  BMC Nephrol       Date:  2015-08-01       Impact factor: 2.388

7.  Urinary adiponectin and progression of diabetic nephropathy in type 1 diabetes.

Authors:  Kyoung Hwa Ha; Dae Jung Kim
Journal:  J Diabetes Investig       Date:  2015-10-15       Impact factor: 4.232

8.  Development of fully automated and ultrasensitive assays for urinary adiponectin and their application as novel biomarkers for diabetic kidney disease.

Authors:  Toshihiro Watanabe; Yuki Fujimoto; Aya Morimoto; Mai Nishiyama; Akinori Kawai; Seiki Okada; Motohiro Aiba; Tomoharu Kawano; Mina Kawahigashi; Masashi Ishizu; Hiroyasu Mori; Munehide Matsuhisa; Akiko Hata; Makoto Funaki; Seiichi Hashida
Journal:  Sci Rep       Date:  2020-09-28       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.